 |
7 Diseases |  |
1 Trial |
|
1 Trial |  |
8 News |  |
- [VIRTUAL] Unique NTRK3 Fusion in a Spindle Cell Sarcoma () - Sep 18, 2021 - Abstract #CAP2021CAP_586;
He had a poor response and subsequently died from pulmonary complications related to metastases to the lungs. The fusion partner MEF2A has not previously been reported and may be related to being refractory to therapy and the poor outcome.
- || belizatinib (TSR-011) / GSK
Clinical, P1 data, Journal: A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. (Pubmed Central) - Mar 18, 2020
P1/2
Limited clinical activity was observed. Based on the competitive ALK inhibitor landscape and benefit/risk considerations, further TSR-011 development was discontinued.
- | belizatinib (TSR-011) / GSK
Journal: Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS. (Pubmed Central) - Jan 10, 2020
We propose that the tertiary nitrogen in the piperidine ring activates the attached benzyl carbon in addition to the two α carbons inside the ring. To our knowledge, this is the first report on the structural identification of reactive metabolites derived from BZB.
- ||| belizatinib (TSR-011) / GSK
Trial completion, Trial completion date, Metastases: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov) - Apr 19, 2019
P1/2, N=72, Completed, Sponsor: Tesaro, Inc.
To our knowledge, this is the first report on the structural identification of reactive metabolites derived from BZB. Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2018
- | Review, Journal: Targeting TRK family proteins in cancer. (Pubmed Central) - Nov 1, 2017
Interim data examining NTRK-rearranged tumors treated with entrectinib or LOXO-101 demonstrate encouraging activity, with patients achieving rapid and durable responses. Consequently, both drugs have achieved orphan designation from regulatory agencies, and efforts are underway to further expedite their development.
- ||| belizatinib (TSR-011) / GSK
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov) - Mar 9, 2016
P1/2, N=72, Active, not recruiting, Sponsor: Tesaro, Inc.
Consequently, both drugs have achieved orphan designation from regulatory agencies, and efforts are underway to further expedite their development. Recruiting --> Active, not recruiting | N=150 --> 72 | Trial primary completion date: Dec 2015 --> Jul 2016
- || belizatinib (TSR-011) / GSK
Trial primary completion date, Metastases: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov) - Feb 20, 2015
P1/2, N=150, Recruiting, Sponsor: Tesaro, Inc.
Recruiting --> Active, not recruiting | N=150 --> 72 | Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- ||||| belizatinib (TSR-011) / GSK
New P1/2 trial, Metastases: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov) - Jan 27, 2014
P1/2, N=150, Recruiting, Sponsor: Tesaro, Inc.